

# CareStart<sup>TM</sup> COVID-19 ANTIGEN RAPID TESTS

FDA EUA Authorized POC Approved / No Lab Requirement

# CareStart™ COVID-19 ANTIGEN RAPID TESTS



### CareStart TM COVID-19 ANTIGEN RAPID TESTS




### **Features**

- Identify individual's current infection status to COVID-19
- Fast and easy to use in Point-of-Care setting
- Qualitatively detect the SARS-CoV-2 nucleocapsid protein
- Use nasopharyngeal (NP) swab specimens
- Reliable results only in 10 minutes
- No special equipment or training required
- All-in-one package including collection swabs
- High sensitivity (88.4%) and specificity (100%)


# **Kit Components**

- 20 test devices
- 20 extraction vials and caps
- 20 NP swabs
- 1 positive and 1 negative controls
- Package insert
- Quick reference Instructions (QRI)


# Nasopharyngeal (NP) Swab Collection




1 Remove a swab from the pouch.



Place the swab into one of patient's nostrils until it reaches the posterior nasopharynx.



Slowly rotate 5 times the swab over the surface of the posterior nasopharynx.




Remove the swab from the nostril.


- Nasopharyngeal is the CDC recommendation for an upper respiratory specimen collection and testing.
- However, other acceptable collection methods such as anterior nares (nasal) is being evaluated because of its less complex and minimal invasive nature. Nasal specimen can be collected by home or supervised onsite self-collection using a flocked or spun polyester swab.

### CareStart™ COVID-19 ANTIGEN RAPID TEST


#### **Test Procedure**




5 Peel off aluminum foil seal.



Place the swab into the extraction vial. Rotate the swab vigorously at least 5 times.




Remove the swab by rotating against the extraction vial while squeezing the sides of the vial to release the liquid from the swab. Properly discard the swab.



8 Close the vial by pushing the cap firmly onto the vial.




9 Mix thoroughly by flicking the bottom of the tube.




10 Invert the extraction vial and hold the sample vertically above the sample well. Squeeze the vial gently. Allow three (3) drops of sample to fall into the sample well.






# Result Interpretation SARS-CoV-2 Positive Negative C T T



- Any faint colored line(s) in the test region(s) should be considered as positive.



- Re-run the test one time using the remaining specimen in the extraction vial.

### ANALYTICAL SPECIFICITY FOR ANTIGEN RAPID TESTS

### **Cross-reactivity**

Viruses listed below are confirmed not to have cross-reactivity with *CareStart*<sup>TM</sup> COVID-19 Antigen.

- Adenovirus 1
- Adenovirus 7
- Enterovirus 71, Tainan/4643/1998
- Human coronavirus (OC43)
- Human coronavirus (229E)
- Human coronavirus (NL63)
- Human metapneumovirus (hMPV)
- Influenza A/Michigan/45/2015
- Influenza B/Wisconsin/01/2010
- MERS-Coronavirus, Irradiated Lysate
- Parainfluenza virus type 1
- Parainfluenza virus type 2
- Parainfluenza virus type 3
- Parainfluenza virus type 4
- Respiratory syncytial virus type B
- Rhinovirus
- Pooled human nasal wash

Bacteria listed below are confirmed not to have interference with *CareStart*<sup>TM</sup> COVID-19 Antigen.

- Bodetella pertussis
- Candida albicans
- Chlamydophila pneumoniae
- Haemophilus influenzae
- Legionella pneumophila
- Mycoplasma pneumoniae
- Streptococcus pneumoniae
- Streptococcus pyogenes, Group A
- Acetaminophen
- Acetyl salicylic acid
- Beclomethasone
- Benzocaine
- Budesonide
- Chlorpheniramine maleate
- Dexamethasone
- Dextromethorphan HBr
- Diphenhydramine HCI
- Ephedrine HCI
- Flunisolide

### COVID-19 ANTIGEN CLINICAL PERFORMANCE

### CareStart<sup>TM</sup> COVID-19 Antigen (retrospective samples) Against Comparator PCR Method with Nasopharyngeal Swabs

CareStart™ COVID-19 Antigen	PCR Comparator		
	Positive	Negative	Total
Positive	38	0	38
Negative	5	63	68
Total	43	63	106
Positive Percent Agreement (PPA)	88.4% (95% CI: 75.52% - 94.93%)		
Negative Percent Agreement (NPA)	100% (95% CI: 94.25% - 100%)		

### CareStart<sup>TM</sup> COVID-19 Antigen (near cut-off samples) Against Comparator PCR Method with Nasopharyngeal Swabs

Samples	Overall % Agreement
True negative (zero analytes)	100% (10/10)
Low positive (2x LoD)	100% (10/10)

## COVID-19 ANTIGEN TEST COMPARISON

Test	Access Bio	Becton Dickinson
Technique	Lateral flow chromatographic immunoassay	Lateral flow chromatographic immunoassay
Instrument	No	Veritor Plus Analyzer (\$400)
Preparation Time	None	None
Known Cross Reactivity	No	No
Processing time	10 minutes	15 minutes
Clinical Sensitivity	88.4%	84%
Clinical Specificity	100%	100%
Specimen Type	Nasopharygeal swabs	Nasal swabs
Analytical Sensitivity (LOD)	8x10 <sup>2</sup> TCID <sub>50</sub> /mL	1.4x10 <sup>2</sup> TCID <sub>50</sub> /mL
Point-of-Care	Yes	Yes
Target	Nucleocapsid antigen	Nucleocapsid antigen

<sup>\*</sup> Quidel Requires 3 year contract of flu tests in order to purchase antigen tests

